- Strengthens its portfolio in Immunoassays for infectious diseases through state-of-the-art technology
- To launch 125 test menus in esoteric testing areas over a period of two years
- Transasia’s 14th overseas acquisition in the last eight years
Mumbai, 6 September, 2017: In continuation of its strategy to gain access of latest in technologies through acquisitions globally, Mumbai based Transasia Bio-Medicals Ltd., India’s leading In-vitro Diagnostic player, has acquired Calbiotech Inc. USA for an undisclosed amount. This is the 14th such overseas acquisition by Transasia in the last eight years. The acquisition of Calbiotech Inc. will help Transasia to further expand its immunology portfolio and strengthen its presence in ELISA and CLIA assays. Over the course of next two years, it will enable Transasia to introduce over 125 new products in esoteric testing such as neonatal screening, cancer and cardiac markers, drugs of abuse, autoimmune and infectious disease testing, allergy markers, Vitamin D and T3 & T4 ELISAs, parameters for anemia, diabetes, steroid and growth factors. Some of these menus will be available in the coming few months.
Calbiotech Inc. brings to the table, a range of ELISA and CLIA assays, with more than 200 products distributed to over 80 countries. It is the first company to introduce immunoassay kits in the USA to detect antibodies against Zika virus in human blood. It is also known for its innovative products for the emerging markets. In addition, Calbiotech Inc. also has a veterinary product group, manufacturing specialized products for veterinary diagnostics. These products will complement some of Transasia’s veterinary products from other group companies. Moduline systems, another group company of Calbiotech, is a manufacturer of high precision liquid dispensing systems including microplate-dispensing and vial-filling equipment that continues to grow and offers versatility to IVD manufacturers.
About the latest acquisition, Mr. Y. S. Prabhakar, Chief Executive Officer, Transasia, commented that “The acquisition has come at a right time, when there is an alarming burden on the society from both communicable and non-communicable diseases in India. 70% of the treatment decisions are based on lab results”.
Speaking on the occasion, Mr. Suresh Vazirani, Chairman & Managing Director, Transasia-Erba Group said, “Calbiotech Inc. and Dr. Noori Barka have developed an excellent range of immunoassay products that will complement our growing range of diagnostic products. Globally the immunology segment of the IVD Industry is valued at around US$ 15 billion. Calbiotech’s expertise in Immunoassay will allow us to strengthen our position in this high growth market and integrate their strong R&D programme to further enhance the product development strategy of the Transasia- Erba Group.”
The immunology segment contributes 30% of the total IVD testing and is valued at USD 15 billion globally.
Transasia has always focused on offering a one stop solution with the latest quality, affordable products backed by a strong sales network spread across India. Going forward, laboratories stand to benefit as they now would have access to a comprehensive immunoassay portfolio from Transasia, thereby eliminating the need to deal with multiple suppliers in this competitive and regulated industry. With this acquisition, Transasia continues to pool in cutting-edge technologies from the developed countries, to offer indigenously manufactured state of the art and affordable products for India and the emerging markets.
About Transasia-Erba Group
Transasia Bio-Medicals Ltd. offers a comprehensive product portfolio spanning all specialties of diagnostics including biochemistry, hematology, immunoassay & blood banking, urinalysis, diabetes, critical care, coagulation, microbiology and molecular diagnostics. Along with its subsidiaries in Germany, France, Czech Republic, Russia, Turkey, UK and USA, Transasia now reaches out to millions in over 104 countries.
Constantly striving to better its best and innovating to serve customers better is one of the key growth drivers at the Transasia-Erba Group. With a dedicated team of experts the Group has created an impressive track record of successful projects. With manufacturing facilities in India, USA and Czech Republic the Group offers innovative products with latest technologies to meet the changing customer needs of both the developed and the developing markets.
For more information, please visit www.transasia.co.in
Calbiotech is a worldwide leader in immunoassay development and manufacturing. It is the first company to introduce immunoassay kits in the United States to detect antibodies against Zika virus in human blood. Calbiotech’s commitment to state-of-the-art technologies and automation helps ensure high-quality, stable, flexible, automation-ready, and cost effective products and services.It has more than 200 products, distributed to more than 80 countries.
The group operates under cGMP and ISO 13485 Standards in an FDA Registered Facility in San Diego, California.
For more information, please visit www.calbiotech.com